Navigation Links
Soliris(R) Reduced Measures of Thrombosis and Inflammation, and Decreased Indicators of Pulmonary Hypertension, in Studies of Patients with PNH
Date:12/9/2008

itional clinical indications, and is pursuing development of other antibody product candidates in early stages of development. This press release

and further information about Alexion Pharmaceuticals, Inc. can be found at: www.alexionpharm.com.


    [ALXN-G]

Safe Harbor Statement

This news release contains forward-looking statements, including statements related to potential health and medical benefits from Soliris. Forward-looking statements are subject to factors that may cause Alexion's results and plans to differ from those expected, including for example, decisions of regulatory authorities regarding marketing approval or material limitations on the marketing of Soliris, delays in arranging satisfactory manufacturing capability and establishing commercial infrastructure, delays in developing or adverse changes in commercial relationships, the possibility that results of clinical trials are not predictive of safety and efficacy results of Soliris in broader patient populations, the possibility that initial results of commercialization are not predictive of future rates of adoption of Soliris, the risk that third parties won't agree to license any necessary intellectual property to Alexion on reasonable terms or at all, the risk that third party payors will not reimburse for the use of Soliris at acceptable rates or at all, the risk that estimates regarding the number of PNH patients are inaccurate, the risk that pending litigation may be resolved adversely, and a variety of other risks set forth from time to time in Alexion's filings with the Securities and Exchange Commission, including but not limited to the risks discussed in Alexion's Quarterly Report on Form 10-Q for the period ended September 30, 2008 and in Alexion's other filings with the Securities and Exchange Commission. Alexion does not intend to update any of thes
'/>"/>

SOURCE Alexion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Alexions Soliris(R) Receives 2008 Prix Galien USA Award for Best Biotechnology Product
2. Alexion Acquires All Rights to OMRF Patents Related to Soliris(R)
3. Treatment with Paliperidone ER May Be Associated with Significantly Reduced Use of Mental Health Resources
4. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
5. New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo
6. UCB Announces New Data Showing Investigational Drug Lacosamide Significantly Reduced Seizures in Refractory Epilepsy Patients
7. Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo
8. Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy
9. PharmAthene Signs Agreement with Medison Pharma Ltd. to Commercialize and Distribute Biodefense Medical Countermeasures in Israel
10. NIST studies how new helium ion microscope measures up
11. SpectraCell Laboratories Now Measures Vitamin C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... is rarely simple. From crop yields to disease risks, ... those considered "complex traits." Just as for heightthe textbook ... particular human disease are shaped by multiple genetic and ... involved. To track down such genes, geneticists typically mate ... large mouse and a small mouseand then study their ...
(Date:9/19/2014)... light, rather than electricity, to move data would ... is a growing concern as chips, transistor counts ... optical circuits light emitters, modulators, and detectors ... promising light source for optical chips is molybdenum ... deposited as a single, atom-thick layer. Other experimental ...
(Date:9/19/2014)... 2014  An entire month is dedicated to one ... Charcot-Marie-Tooth disease (CMT) – a debilitating neuromuscular disease affecting ... atrophy, weakness, and foot and hand deformities. CMT affects ... CMT is a progressive disease, and over time patients ... devices such as leg braces, wheelchairs and scooters to ...
(Date:9/19/2014)... 2014  Nektar Therapeutics (NASDAQ: NKTR ... the analgesic profiles of a series of the ... molecules. The preclinical research candidates were created using ... The analgesic properties of kappa receptor agonism ... Kappa opioid receptors are expressed in the ...
Breaking Biology Technology:Want to link genes to complex traits? Start with more diversity 2Toward optical chips 2Toward optical chips 3September is Charcot-Marie-Tooth (CMT) Awareness Month - Scheduled events, activities and important partnerships announced throughout the month! 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 5
... leading provider of room-temperature biosample transport, storage and ... 3.2, the newest version of its software for ... include a strategic licensing model that enables GenConnect ... as well as a new customer licensing model ...
... Crystal Research Associates, LLC announced today that it ... Biotech, Inc. The full 56-page report can be found ... Biotech" or "the Company") is a closely held pharmaceutical ... novel cancer therapeutics. Following a technology spinout from Bayer ...
... Conference Call and Webcast to FollowTHE WOODLANDS, Texas, April ... ) will release its first quarter 2009 financial results ... open. Lexicon management will hold a conference call ... for first quarter 2009 at 11:00 a.m. Eastern Time ...
Cached Biology Technology:GenVault Corporation Launches its Latest Centralized and Standardized Software Solution for Biobanking and Biological Sample Management, GenConnect 3.2 2GenVault Corporation Launches its Latest Centralized and Standardized Software Solution for Biobanking and Biological Sample Management, GenConnect 3.2 3Crystal Research Associates, LLC Issues an Executive Informational Overview(R) (EIO(R)) on ACT Biotech, Inc. 2Crystal Research Associates, LLC Issues an Executive Informational Overview(R) (EIO(R)) on ACT Biotech, Inc. 3Lexicon to Provide Clinical Pipeline Update and Report First Quarter 2009 Financial Results on April 28, 2009 2
(Date:9/18/2014)... New research has found clownfish larvae can swim up to ... better able to cope with environmental change. , Clownfish spend ... anemone but as babies they must wander the open ocean, ... of Excellence for Coral Reef Studies (Coral CoE) at James ... they go, but now we,ve been given a rare glimpse ...
(Date:9/17/2014)... of the Santa Ana Wildfire Threat Index a ... the powerful, hot, dry Santa Ana wind, which can ... introduced Sept. 17 by the U.S. Forest Service, in ... , The index includes four classification levels ranging from ... fire agencies and other emergency responders, the media and ...
(Date:9/17/2014)... in 2000 as an EC-FP5 four-year project, delivering its ... progress and successful participations in several EC projects, as ... Network project (EU BON), to increase the general ... to extend the general dissemination of the Fauna Europaea ... has applied its novel e-Publishing tools to prepare data ...
Breaking Biology News(10 mins):Nemo's epic journey to find a new home 2UCLA scientists play key role in developing new Santa Ana Wildfire Threat Index 2Contributions on Fauna Europaea: Data papers as innovative model on expert involvement 2
... San Francisco A human monoclonal antibody developed ... (UMMS) given to patients with chronic hepatitis C virus ... for at least a week after transplant and delayed ... double-blind, placebo-controlled, phase 2 study were presented this week ...
... the nature of crowds playing Foldit called some strategies ... methods already used by protein scientists., Gamers made headlines ... central to research on AIDS. Today, in a ... National Academy of Sciences, University of Washington researchers ...
... CORONA, Calif., Nov. 7, 2011 AVT, Inc. (formerly ... partnered with MedBox to provide a new line of ... Fingerprint Recognition System. This new system provides ... and verification of the customer is critical. ...
Cached Biology News:Experimental drug suppresses rebound of hepatitis C virus in liver transplant patients 2Experimental drug suppresses rebound of hepatitis C virus in liver transplant patients 3Paper uncovers power of Foldit gamers' strategies 2Paper uncovers power of Foldit gamers' strategies 3AVT Partners with MedBox to Provide New Biometric Fingerprint Recognition for Secure Automated Retailing 2
... Gel-Digesting Preparation contains a unique β-agarose digesting ... recovery of intact DNA and RNA from ... electrophoresis in TAE, TBE, MOPS, or phosphate ... in the TAE, TBE, MOPS, and phosphate ...
Request Info...
... Electron RapidStak provides valuable walk-away time and ... buffer nest technology for parallel processing of ... fast, reliable automation for any laboratory in ... The RapidStak can be set-up within minutes ...
... Benzonase Nuclease is a genetically engineered endonuclease. ... DNA and RNA while having no proteolytic ... range of conditions and possesses an exceptionally ... nucleic acids from recombinant proteins, its use ...
Biology Products: